© 2021 MJH Life Sciences and Neurology Live. All rights reserved.
© 2021 MJH Life Sciences™ and Neurology Live. All rights reserved.
Chief medical officer, Biohaven Pharmaceuticals
June 07, 2021
The chief medical officer of Biohaven Pharmaceuticals discussed the findings of an assessment of rimegepant (Nurtec ODT) exposure with concomitant administration of inhibitors of P-gp and BCRP transporters.